// App-Quantinova.ai

S220 : GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS

Researchers

Presenter

  • Michael Dickinson

Principal Investigators

  • Franck Morschhauser

  • Emmanuel Bachy

  • Paolo Corradini

  • Gloria Iacoboni

  • Cyrus Khan

  • Thomasz Wrbel

  • Fritz Offner

  • Marek Trnen

  • Shang-Ju Wu

  • Guillaume Cartron

  • Mark Hertzberg

  • Anna Sureda

  • David Perez-Callejo

  • Linda Lundberg

  • James Relf

  • Emma Clark

  • Kathryn Humphrey

  • Martin Hutchings

Medical Centers

  • Rigshospitalet, Copenhagen, Denmark

  • Roche - F.Hoffman-La Roche Ltd,Basel,Швейцария

  • Rigshospitalet, Copenhagen, Denmark

  • Humanitas University and IRCCS Humanitas

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Centre Hospitalier Lyon-Sud,Lyon,Frankrijk

  • Roche Products Ltd,Welwyn Garden City,Royaume-uni

  • Uniwersytet Medyczny we Wrocławiu,Wroclaw,Poland

  • Roche Products Ltd,Welwyn Ga

  • Allegheny Health

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Charles University Hospital,Prague,Чехия

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • CHU de Montpellier, Montpellier, France

  • Università degli Studi di Milano and Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori,Milan,Italien

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Centre Hospitalier Lyon-Sud,Lyon,Frankrijk

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Roche Products Ltd,Welwyn Garden City,Reino Unido

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • F. Hoffmann-La Roche Ltd ,Basel,Suisse

  • CHU de Montpellier, Montpellier, France

  • Rigshospitalet, Copenhagen, Denmark

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Allegheny Health Network, Pittsburgh, PA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Rigshospitalet, Copenhagen, Denmark

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital and

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Allegheny Health Network,Pittsburgh, PA,Estados Unidos

  • F. Hoffmann-La Roche Ltd ,Basel,Suisse

  • Centre Hospitalier Lyon-Sud,Lyon,Frankrijk

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australien

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • CHU de Montpellier, Montpellier, France

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • Allegheny Health Network, Pittsburgh, PA, United States.

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Charles University Hospital,Prague,República Tcheca

  • Charles University Hospital,Prague,Rep. Ceca

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Centre Hospitalier Lyon-Sud,Lyon,Франция

  • Institut Català d'Oncolo

  • Allegheny Health Network, Pittsburgh, PA, United States.

  • Centre Hospitalier Lyon-Sud,Lyon,Frankrijk

  • Roche Products Ltd,Welwyn Garden City,Reino Unido

  • F. Hoffmann-La Roche Ltd ,Basel,Suisse

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australien

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • National Taiwan University Hospital​,Taipei,Taïwan, Province De Chine

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australie

  • Hôpital Claude Huriez and CHU de Lille,Lille,Frankrijk

  • Charles University General Hospital,Prague,Tsjechische Republiek

  • Allegheny Health Network,Pittsburgh, PA,Estados Unidos

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Charles University Hospital,Prague,Czech

  • Rigshospitalet, Copenhagen, Denmark

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Uniwer

  • Charles University General Hospital,Prague,Tsjechische Republiek

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Centre Hospitalier Lyon-Sud,Lyon,Frankrijk

  • Allegheny Health Network, Pittsburgh, PA, United States.

  • Roche Products Ltd,Welwyn Garden City,Verenigd Koninkrijk

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Università degli Studi di Milano and Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori,Milan,Italien

  • F. Hoffmann-La Roche Ltd ,Basel,Suisse

  • Charles University General Hospital,Prague,Tsjechische Republiek

  • Hôpital Claude Huriez and C

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • Charles University Hospital,Prague,República Tcheca

  • CHU de Montpellier, Montpellier, France

  • CHU de Montpellier, Montpellier, France

  • Uniwersytet Medyczny we Wrocławiu,Wroclaw,Poland

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australie

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Uniwersytet Medyczny we Wrocławiu,Wroclaw,Poland

  • Università degli Studi di Milano and Fondazione Istituti di Ricovero e Cura a Carattere Scientifi

  • Uniwersytet Medyczny we Wrocławiu,Wroclaw,Poland

  • Uniwersytet Medyczny we Wrocławiu,Wroclaw,Poland

  • CHU de Montpellier,Montpellier,Франция

  • CHU de Montpellier, Montpellier, France

  • Roche Products Ltd,Welwyn Garden City,Verenigd Koninkrijk

  • Rigshospitalet, Copenhagen, Denmark

  • Oncology,National Taiwan University Hospital,Taipei,Republik China (Taiwan)

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Rigshospitalet,Copenhagen,Дания

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Universitair Ziekenhuis Gent, Ghent, Belgium

Locations

  • United States

  • Australia

  • Italy

  • France

  • Venezuela

  • Spain

  • Poland

  • Belgium

  • Czech Republic

  • Taiwan

  • China

  • Canada

  • Switzerland

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • B cell lymphomas

Biomarkers

  • Cytokeratin 20

  • Twist-related protein 1

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03075696

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved